Associated Papers
Decoding variants in drug-metabolizing enzymes and transporters in solid tumor patients by whole-exome sequencing.
Aboul-Soud MAM et al.
Saudi Journal of Biological Sciences, 2021
33424349 (PubMed )
Supplement: mmc1.xlsx › Sheet1
Targeted next generation sequencing as a tool for precision medicine.
Gulilat M et al.
Bmc Medical Genomics, 2019
31159795 (PubMed )
Supplement: 12920_2019_527_MOESM1_ESM.xlsx › Table_S6
Polymorphism of dopamine D2 receptor (TaqIA, TaqIB, and-141C Ins/Del) and dopamine degradation enzyme (COMT G158A, A-278G) genes and extrapyramidal symptoms in patients with schizophrenia and bipolar disorders.
Lafuente A et al.
Psychiatry Research, 2008
From dopaminergic genes to psychiatric disorders.
Hoenicka J et al.
Neurotoxicity Research, 2007
Pharmacogenetics as a tool in the therapy of schizophrenia.
Wilffert B et al.
Pharmacy World & Science : Pws, 2005
Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor.
Duan J et al.
Human Molecular Genetics, 2003
Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia.
Kaiser R et al.
Molecular Psychiatry, 2002
Select a paper to view details